Sign up to save your podcasts
Or
Share Managing HK in HF: Navigating the Evolving Clinical Landscape
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing HK in HF: Navigating the Evolving Clinical Landscape
CME credits: 0.25
Valid until: 17-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/managing-hk-in-hf-navigating-the-evolving-clinical-landscape/13029/
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 17-11-2022
Claim your CME credit at https://reachmd.com/programs/cme/managing-hk-in-hf-navigating-the-evolving-clinical-landscape/13029/
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.